Compile Data Set for Download or QSAR
Found 17353 Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase JAK1'
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM473569(US10844057, Example 12 | US10947229, Example 5)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C30H35N7O2/c1-5-11-36-17-26-25(14-27(36)30(39)37-15-20(16-37)35(3)4)31-29(32-26)28-23-9-7-19(13-24(23)33-34-28)22-10-8-21(38)12-18(22)6-2/h7-10,12-13,20,27,38H,5-6,11,14-17H2,1-4H3/b29-28-/t27-/m0/s1
Affinity DataKi:  0.0320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM473569(US10844057, Example 12 | US10947229, Example 5)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C30H35N7O2/c1-5-11-36-17-26-25(14-27(36)30(39)37-15-20(16-37)35(3)4)31-29(32-26)28-23-9-7-19(13-24(23)33-34-28)22-10-8-21(38)12-18(22)6-2/h7-10,12-13,20,27,38H,5-6,11,14-17H2,1-4H3/b29-28-/t27-/m0/s1
Affinity DataKi:  0.0320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(Cc2[nH]1)C(C)C)C(=O)N1CC(C1)N(C)C
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-10-27(39)22(31)11-21(17)18-7-8-20-23(9-18)34-35-28(20)29-32-24-12-26(38(16(2)3)15-25(24)33-29)30(40)37-13-19(14-37)36(4)5/h7-11,16,19,26,39H,6,12-15H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(Cc2[nH]1)C(C)C)C(=O)N1CC(C1)N(C)C
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-10-27(39)22(31)11-21(17)18-7-8-20-23(9-18)34-35-28(20)29-32-24-12-26(38(16(2)3)15-25(24)33-29)30(40)37-13-19(14-37)36(4)5/h7-11,16,19,26,39H,6,12-15H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM473567(US10844057, Example 10 | US10947229, Example 3)
Show SMILES CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C30H35N7O2/c1-6-18-12-20(38)9-11-21(18)19-8-10-22-23(13-19)33-34-27(22)28-31-24-14-26(36(7-2)15-25(24)32-28)29(39)37-16-30(3,17-37)35(4)5/h8-13,26,38H,6-7,14-17H2,1-5H3/b28-27-/t26-/m0/s1
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(Cc2[nH]1)C(C)C)C(=O)N1CC(C1)N(C)C
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-10-27(39)22(31)11-21(17)18-7-8-20-23(9-18)34-35-28(20)29-32-24-12-26(38(16(2)3)15-25(24)33-29)30(40)37-13-19(14-37)36(4)5/h7-11,16,19,26,39H,6,12-15H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM473567(US10844057, Example 10 | US10947229, Example 3)
Show SMILES CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C30H35N7O2/c1-6-18-12-20(38)9-11-21(18)19-8-10-22-23(13-19)33-34-27(22)28-31-24-14-26(36(7-2)15-25(24)32-28)29(39)37-16-30(3,17-37)35(4)5/h8-13,26,38H,6-7,14-17H2,1-5H3/b28-27-/t26-/m0/s1
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(Cc2[nH]1)C(C)C)C(=O)N1CC(C1)N(C)C
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-10-27(39)22(31)11-21(17)18-7-8-20-23(9-18)34-35-28(20)29-32-24-12-26(38(16(2)3)15-25(24)33-29)30(40)37-13-19(14-37)36(4)5/h7-11,16,19,26,39H,6,12-15H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(Cc2[nH]1)C(C)C)C(=O)N1CC(C1)N(C)C
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-10-27(39)22(31)11-21(17)18-7-8-20-23(9-18)34-35-28(20)29-32-24-12-26(38(16(2)3)15-25(24)33-29)30(40)37-13-19(14-37)36(4)5/h7-11,16,19,26,39H,6,12-15H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350089(((S)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1C[C@@H]2C[C@H]1CN2C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H34FN7O2/c1-4-8-38-16-26-25(13-27(38)31(41)39-15-19-11-20(39)14-37(19)3)33-30(34-26)29-21-7-6-18(9-24(21)35-36-29)22-12-23(32)28(40)10-17(22)5-2/h6-7,9-10,12,19-20,27,40H,4-5,8,11,13-16H2,1-3H3/b30-29-/t19-,20-,27-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H36FN7O2/c1-6-10-38-15-25-24(14-26(38)30(41)39-16-31(3,17-39)37(4)5)33-29(34-25)28-20-9-8-19(11-23(20)35-36-28)21-13-22(32)27(40)12-18(21)7-2/h8-9,11-13,26,40H,6-7,10,14-17H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM521924(N-[3-[6-(difluoromethoxy)-3- oxo-4H-1,4-benzothiaz...)
Show SMILES FC(F)Oc1cc2NC(=O)CSc2cc1-c1n[nH]cc1NC(=O)c1cnn2cccnc12
Show InChI InChI=1S/C19H13F2N7O3S/c20-19(21)31-13-5-11-14(32-8-15(29)25-11)4-9(13)16-12(7-23-27-16)26-18(30)10-6-24-28-3-1-2-22-17(10)28/h1-7,19H,8H2,(H,23,27)(H,25,29)(H,26,30)
Affinity DataKi:  0.0500nMAssay Description:The activity of the isolated recombinant JAK1 and JAK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM488306(US10954237, Example 8-9)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(C)Cc2[nH]1)C(=O)N1CC(C)(C1)N(C)C
Show InChI InChI=1S/C29H32FN7O2/c1-6-16-10-25(38)20(30)11-19(16)17-7-8-18-21(9-17)33-34-26(18)27-31-22-12-24(36(5)13-23(22)32-27)28(39)37-14-29(2,15-37)35(3)4/h7-11,24,38H,6,12-15H2,1-5H3/b27-26-/t24-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM431910(US10550118, Example 8-17 | US10954237, Example 8-1...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@@H](N(Cc2[nH]1)C(C)C)C(=O)N1CC(C1)N(C)C
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-10-27(39)22(31)11-21(17)18-7-8-20-23(9-18)34-35-28(20)29-32-24-12-26(38(16(2)3)15-25(24)33-29)30(40)37-13-19(14-37)36(4)5/h7-11,16,19,26,39H,6,12-15H2,1-5H3/b29-28-/t26-/m1/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM431913(US10550118, Example 8-20 | US10954237, Example 8-2...)
Show SMILES CCN1Cc2[nH]c(nc2C[C@@H]1C(=O)N1CC(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C29H32FN7O2/c1-5-16-10-26(38)21(30)11-20(16)17-7-8-19-22(9-17)33-34-27(19)28-31-23-12-25(36(6-2)15-24(23)32-28)29(39)37-13-18(14-37)35(3)4/h7-11,18,25,38H,5-6,12-15H2,1-4H3/b28-27-/t25-/m1/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM431914(US10550118, Example 8-21 | US10954237, Example 8-2...)
Show SMILES CCN1Cc2[nH]c(nc2C[C@@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-11-26(39)21(31)12-20(17)18-8-9-19-22(10-18)34-35-27(19)28-32-23-13-25(37(7-2)14-24(23)33-28)29(40)38-15-30(3,16-38)36(4)5/h8-12,25,39H,6-7,13-16H2,1-5H3/b28-27-/t25-/m1/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333145((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(5-et...)
Show SMILES CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-11-26(39)21(31)12-20(17)18-8-9-19-22(10-18)34-35-27(19)28-32-23-13-25(37(7-2)14-24(23)33-28)29(40)38-15-30(3,16-38)36(4)5/h8-12,25,39H,6-7,13-16H2,1-5H3/b28-27-/t25-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM472922(US10836763, Example 5 | US10844057, Example 5)
Show SMILES CCc1cc(O)ccc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(C)Cc2[nH]1)C(=O)N1CCN(CCO)C[C@H]1C
Show InChI InChI=1S/C30H35N7O3/c1-4-19-13-21(39)6-8-22(19)20-5-7-23-24(14-20)33-34-28(23)29-31-25-15-27(35(3)17-26(25)32-29)30(40)37-10-9-36(11-12-38)16-18(37)2/h5-8,13-14,18,27,38-39H,4,9-12,15-17H2,1-3H3/b29-28-/t18-,27+/m1/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM472914(US10836763, Example 2 | US10844057, Example 2)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1C[C@@H]2C[C@H]1CN2C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C31H35N7O2/c1-4-10-37-17-27-26(14-28(37)31(40)38-16-20-13-21(38)15-36(20)3)32-30(33-27)29-24-8-6-19(12-25(24)34-35-29)23-9-7-22(39)11-18(23)5-2/h6-9,11-12,20-21,28,39H,4-5,10,13-17H2,1-3H3/b30-29-/t20-,21-,28-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM472922(US10836763, Example 5 | US10844057, Example 5)
Show SMILES CCc1cc(O)ccc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(C)Cc2[nH]1)C(=O)N1CCN(CCO)C[C@H]1C
Show InChI InChI=1S/C30H35N7O3/c1-4-19-13-21(39)6-8-22(19)20-5-7-23-24(14-20)33-34-28(23)29-31-25-15-27(35(3)17-26(25)32-29)30(40)37-10-9-36(11-12-38)16-18(37)2/h5-8,13-14,18,27,38-39H,4,9-12,15-17H2,1-3H3/b29-28-/t18-,27+/m1/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2)
Show SMILES CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C29H33N7O2/c1-5-17-11-20(37)8-10-21(17)18-7-9-22-23(12-18)32-33-27(22)28-30-24-13-26(35(6-2)16-25(24)31-28)29(38)36-14-19(15-36)34(3)4/h7-12,19,26,37H,5-6,13-16H2,1-4H3/b28-27-/t26-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM473570(US10844057, Example 13 | US10947229, Example 6)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C31H37N7O2/c1-6-12-37-16-26-25(15-27(37)30(40)38-17-31(3,18-38)36(4)5)32-29(33-26)28-23-10-8-20(14-24(23)34-35-28)22-11-9-21(39)13-19(22)7-2/h8-11,13-14,27,39H,6-7,12,15-18H2,1-5H3/b29-28-/t27-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2)
Show SMILES CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C29H33N7O2/c1-5-17-11-20(37)8-10-21(17)18-7-9-22-23(12-18)32-33-27(22)28-30-24-13-26(35(6-2)16-25(24)31-28)29(38)36-14-19(15-36)34(3)4/h7-12,19,26,37H,5-6,13-16H2,1-4H3/b28-27-/t26-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333145((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(5-et...)
Show SMILES CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-11-26(39)21(31)12-20(17)18-8-9-19-22(10-18)34-35-27(19)28-32-23-13-25(37(7-2)14-24(23)33-28)29(40)38-15-30(3,16-38)36(4)5/h8-12,25,39H,6-7,13-16H2,1-5H3/b28-27-/t25-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM473570(US10844057, Example 13 | US10947229, Example 6)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C31H37N7O2/c1-6-12-37-16-26-25(15-27(37)30(40)38-17-31(3,18-38)36(4)5)32-29(33-26)28-23-10-8-20(14-24(23)34-35-28)22-11-9-21(39)13-19(22)7-2/h8-11,13-14,27,39H,6-7,12,15-18H2,1-5H3/b29-28-/t27-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H36FN7O2/c1-6-10-38-15-25-24(14-26(38)30(41)39-16-31(3,17-39)37(4)5)33-29(34-25)28-20-9-8-19(11-23(20)35-36-28)21-13-22(32)27(40)12-18(21)7-2/h8-9,11-13,26,40H,6-7,10,14-17H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM472914(US10836763, Example 2 | US10844057, Example 2)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1C[C@@H]2C[C@H]1CN2C)-c1n[nH]c2cc(ccc12)-c1ccc(O)cc1CC
Show InChI InChI=1S/C31H35N7O2/c1-4-10-37-17-27-26(14-28(37)31(40)38-16-20-13-21(38)15-36(20)3)32-30(33-27)29-24-8-6-19(12-25(24)34-35-29)23-9-7-22(39)11-18(23)5-2/h6-9,11-12,20-21,28,39H,4-5,10,13-17H2,1-3H3/b30-29-/t20-,21-,28-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350089(((S)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1C[C@@H]2C[C@H]1CN2C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H34FN7O2/c1-4-8-38-16-26-25(13-27(38)31(41)39-15-19-11-20(39)14-37(19)3)33-30(34-26)29-21-7-6-18(9-24(21)35-36-29)22-12-23(32)28(40)10-17(22)5-2/h6-7,9-10,12,19-20,27,40H,4-5,8,11,13-16H2,1-3H3/b30-29-/t19-,20-,27-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM431914(US10550118, Example 8-21 | US10954237, Example 8-2...)
Show SMILES CCN1Cc2[nH]c(nc2C[C@@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-11-26(39)21(31)12-20(17)18-8-9-19-22(10-18)34-35-27(19)28-32-23-13-25(37(7-2)14-24(23)33-28)29(40)38-15-30(3,16-38)36(4)5/h8-12,25,39H,6-7,13-16H2,1-5H3/b28-27-/t25-/m1/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333145((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(5-et...)
Show SMILES CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-11-26(39)21(31)12-20(17)18-8-9-19-22(10-18)34-35-27(19)28-32-23-13-25(37(7-2)14-24(23)33-28)29(40)38-15-30(3,16-38)36(4)5/h8-12,25,39H,6-7,13-16H2,1-5H3/b28-27-/t25-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350089(((S)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1C[C@@H]2C[C@H]1CN2C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H34FN7O2/c1-4-8-38-16-26-25(13-27(38)31(41)39-15-19-11-20(39)14-37(19)3)33-30(34-26)29-21-7-6-18(9-24(21)35-36-29)22-12-23(32)28(40)10-17(22)5-2/h6-7,9-10,12,19-20,27,40H,4-5,8,11,13-16H2,1-3H3/b30-29-/t19-,20-,27-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350094(US10208040, Example 1-2 | US10519153, Example 1-2)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2CC(NCc2[nH]1)C(=O)N1CCN(CC1)C(C)C
Show InChI InChI=1S/C29H32FN7O2/c1-4-17-12-26(38)21(30)13-20(17)18-5-6-19-22(11-18)34-35-27(19)28-32-23-14-24(31-15-25(23)33-28)29(39)37-9-7-36(8-10-37)16(2)3/h5-6,11-13,16,24,31,38H,4,7-10,14-15H2,1-3H3/b28-27-
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM431902(US10550118, Example 8-9)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2CC(N(C)Cc2[nH]1)C(=O)N1CC(C)(C1)N(C)C
Show InChI InChI=1S/C29H32FN7O2/c1-6-16-10-25(38)20(30)11-19(16)17-7-8-18-21(9-17)33-34-26(18)27-31-22-12-24(36(5)13-23(22)32-27)28(39)37-14-29(2,15-37)35(3)4/h7-11,24,38H,6,12-15H2,1-5H3/b27-26-
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM431910(US10550118, Example 8-17 | US10954237, Example 8-1...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@@H](N(Cc2[nH]1)C(C)C)C(=O)N1CC(C1)N(C)C
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-10-27(39)22(31)11-21(17)18-7-8-20-23(9-18)34-35-28(20)29-32-24-12-26(38(16(2)3)15-25(24)33-29)30(40)37-13-19(14-37)36(4)5/h7-11,16,19,26,39H,6,12-15H2,1-5H3/b29-28-/t26-/m1/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM431913(US10550118, Example 8-20 | US10954237, Example 8-2...)
Show SMILES CCN1Cc2[nH]c(nc2C[C@@H]1C(=O)N1CC(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C29H32FN7O2/c1-5-16-10-26(38)21(30)11-20(16)17-7-8-19-22(9-17)33-34-27(19)28-31-23-12-25(36(6-2)15-24(23)32-28)29(39)37-13-18(14-37)35(3)4/h7-11,18,25,38H,5-6,12-15H2,1-4H3/b28-27-/t25-/m1/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350089(((S)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1C[C@@H]2C[C@H]1CN2C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H34FN7O2/c1-4-8-38-16-26-25(13-27(38)31(41)39-15-19-11-20(39)14-37(19)3)33-30(34-26)29-21-7-6-18(9-24(21)35-36-29)22-12-23(32)28(40)10-17(22)5-2/h6-7,9-10,12,19-20,27,40H,4-5,8,11,13-16H2,1-3H3/b30-29-/t19-,20-,27-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350094(US10208040, Example 1-2 | US10519153, Example 1-2)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2CC(NCc2[nH]1)C(=O)N1CCN(CC1)C(C)C
Show InChI InChI=1S/C29H32FN7O2/c1-4-17-12-26(38)21(30)13-20(17)18-5-6-19-22(11-18)34-35-27(19)28-32-23-14-24(31-15-25(23)33-28)29(39)37-9-7-36(8-10-37)16(2)3/h5-6,11-13,16,24,31,38H,4,7-10,14-15H2,1-3H3/b28-27-
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H36FN7O2/c1-6-10-38-15-25-24(14-26(38)30(41)39-16-31(3,17-39)37(4)5)33-29(34-25)28-20-9-8-19(11-23(20)35-36-28)21-13-22(32)27(40)12-18(21)7-2/h8-9,11-13,26,40H,6-7,10,14-17H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H36FN7O2/c1-6-10-38-15-25-24(14-26(38)30(41)39-16-31(3,17-39)37(4)5)33-29(34-25)28-20-9-8-19(11-23(20)35-36-28)21-13-22(32)27(40)12-18(21)7-2/h8-9,11-13,26,40H,6-7,10,14-17H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H36FN7O2/c1-6-10-38-15-25-24(14-26(38)30(41)39-16-31(3,17-39)37(4)5)33-29(34-25)28-20-9-8-19(11-23(20)35-36-28)21-13-22(32)27(40)12-18(21)7-2/h8-9,11-13,26,40H,6-7,10,14-17H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333145((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(5-et...)
Show SMILES CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C30H34FN7O2/c1-6-17-11-26(39)21(31)12-20(17)18-8-9-19-22(10-18)34-35-27(19)28-32-23-13-25(37(7-2)14-24(23)33-28)29(40)38-15-30(3,16-38)36(4)5/h8-12,25,39H,6-7,13-16H2,1-5H3/b28-27-/t25-/m0/s1
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM539139(US11254669, Example 1-2)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2CC(NCc2[nH]1)C(=O)N1CCN(C)CC1
Show InChI InChI=1S/C27H28FN7O2/c1-3-15-11-24(36)19(28)12-18(15)16-4-5-17-20(10-16)32-33-25(17)26-30-21-13-22(29-14-23(21)31-26)27(37)35-8-6-34(2)7-9-35/h4-5,10-12,22,29,36H,3,6-9,13-14H2,1-2H3/b26-25-
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H36FN7O2/c1-6-10-38-15-25-24(14-26(38)30(41)39-16-31(3,17-39)37(4)5)33-29(34-25)28-20-9-8-19(11-23(20)35-36-28)21-13-22(32)27(40)12-18(21)7-2/h8-9,11-13,26,40H,6-7,10,14-17H2,1-5H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350090(((S)-3-(dimethylamino)pyrrolidin-1-yl)((S)-5-ethyl...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(Cc2[nH]1)C(C)C)C(=O)N1CC[C@@H](C1)N(C)C
Show InChI InChI=1S/C31H36FN7O2/c1-6-18-12-28(40)23(32)13-22(18)19-7-8-21-24(11-19)35-36-29(21)30-33-25-14-27(39(17(2)3)16-26(25)34-30)31(41)38-10-9-20(15-38)37(4)5/h7-8,11-13,17,20,27,40H,6,9-10,14-16H2,1-5H3/b30-29-/t20-,27-/m0/s1
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350093((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Show SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CCN(CCO)CC1)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H36FN7O3/c1-3-7-39-18-26-25(17-27(39)31(42)38-10-8-37(9-11-38)12-13-40)33-30(34-26)29-21-6-5-20(14-24(21)35-36-29)22-16-23(32)28(41)15-19(22)4-2/h5-6,14-16,27,40-41H,3-4,7-13,17-18H2,1-2H3/b30-29-/t27-/m0/s1
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350095(US10208040, Example 1-12 | US11254669, Example 1-1...)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(C)Cc2[nH]1)C(=O)N1CCN(CC1)C(C)C
Show InChI InChI=1S/C30H34FN7O2/c1-5-18-13-27(39)22(31)14-21(18)19-6-7-20-23(12-19)34-35-28(20)29-32-24-15-26(36(4)16-25(24)33-29)30(40)38-10-8-37(9-11-38)17(2)3/h6-7,12-14,17,26,39H,5,8-11,15-16H2,1-4H3/b29-28-/t26-/m0/s1
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM472917(US10836763, Example C-3 | US11254669, Example 2-15)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(C)Cc2[nH]1)C(=O)N1CCN(C)C[C@@H]1C
Show InChI InChI=1S/C29H32FN7O2/c1-5-17-11-26(38)21(30)12-20(17)18-6-7-19-22(10-18)33-34-27(19)28-31-23-13-25(36(4)15-24(23)32-28)29(39)37-9-8-35(3)14-16(37)2/h6-7,10-12,16,25,38H,5,8-9,13-15H2,1-4H3/b28-27-/t16-,25-/m0/s1
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM539143(US11254669, Example 9-21)
Show SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](CN3CC[C@@H](C3)N(C)C)N(Cc2[nH]1)C(C)C
Show InChI InChI=1S/C31H38FN7O/c1-6-19-12-29(40)25(32)14-24(19)20-7-8-23-26(11-20)35-36-30(23)31-33-27-13-22(39(18(2)3)17-28(27)34-31)16-38-10-9-21(15-38)37(4)5/h7-8,11-12,14,18,21-22,40H,6,9-10,13,15-17H2,1-5H3/b31-30-/t21-,22+/m0/s1
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM350099(US10208040, Example 12-14 | US11254669, Example 12...)
Show SMILES CCN(CC)CCN(C)C(=O)[C@H]1Cc2nc([nH]c2CN1CC)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC
Show InChI InChI=1S/C31H38FN7O2/c1-6-19-15-28(40)23(32)16-22(19)20-10-11-21-24(14-20)35-36-29(21)30-33-25-17-27(39(9-4)18-26(25)34-30)31(41)37(5)12-13-38(7-2)8-3/h10-11,14-16,27,40H,6-9,12-13,17-18H2,1-5H3/b30-29-/t27-/m1/s1
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D IP, LLC

US Patent
LigandPNGBDBM521949(N-[3-[6-(difluoromethoxy)-2- methyl-3-oxo-4H-1,4- ...)
Show SMILES CC1Sc2cc(-c3n[nH]cc3NC(=O)c3cnn4cccnc34)c(OC(F)F)cc2NC1=O
Affinity DataKi:  0.0600nMAssay Description:The activity of the isolated recombinant JAK1 and JAK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
Displayed 1 to 50 (of 17353 total ) | Next | Last >>
Jump to: